Events | 2019.06.06
Exeltis USA, Inc. Announces the Approval of Slynd™, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window
FLORHAM PARK, N.J., June 6, 2019 /PRNewswire/ -- Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced today that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced "slind") containing drospirenone ...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]sed-pill-window-300863390.html
Follow us on
📊 Most Viewed News
- • The complete guide to making your product international - The Nex... (15,542)
- • Colaboração 2.0: Breaking Down the Language Barrier - Business ... (12,035)
- • A Start-Up Bets on Human Translators Over Machines - New York Tim... (11,530)
- • Immigrants 'should learn English' - Politics.co.uk (11,211)
- • How OpenStack gets translated - opensource.com (11,051)
- • easyJet Chooses TransPerfect for Pan-European Translation - Busin... (10,937)
- • Para-Plus Translations Honored by Philadelphia Business Journal .... (10,367)
- • Google Adds Customized Translations for Website Owners - PC Magaz... (10,257)